Last updated: 2026-09-06 16:46:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Pliant Therapeutics, Inc. (PLRX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.17, with a market capitalization of $71.83M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.02 to $1.95. This page covers its latest market performance, valuation, price trends and company information.
$71.83M | |
$1.12 | |
$43.92 | |
$1.02 | |
$1.13 | |
544.71K | |
-- | |
-- | |
$1.95 | |
$1.02 | |
-- | |
-- |
Pliant Therapeutics, Inc. (PLRX) last closed at $1.13 as of 2026-09-04 23:31:00, unchanged from the previous close of $1.13.
During the latest regular trading session, PLRX traded between $1.02 and $43.92, with a volume of 544.71K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Pliant Therapeutics, Inc. (PLRX) moved from $1.10 to $1.17, representing a gain of 5.91% ($0.06).
The stock traded between $1.11 and $1.18 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 373.24 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 15.6%
PLRX is currently trading at $1.17, placing it 15.6% of the way from its 52-week low of $1.02 to its 52-week high of $1.95. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 49 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Pliant Therapeutics, Inc. (PLRX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.